Search clinical trials for: Anlotinib plus Pemetrexed

Total 7084 results

Fudan University

Active, not recruiting

Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer

Thyroid Cancer

China
Sun Yat-sen University

Unknown

Treating Locally Advanced Head and Neck Malignant Tumor With Anlotinib and Chemoradiotherapy

Head and Neck Cancer

China
Hunan Province Tumor Hospital

Not yet recruiting

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW (WUKONG-32-RW)

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Not yet recruiting

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC (WUKONG-32)

Non-Small Cell Lung Cancer

China
Peking Union Medical College Hospital

Not yet recruiting

Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer

Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma

China
Aduro Biotech, Inc.

Completed

Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma

United States
Sun Yat-sen University

Recruiting

Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation

Breast Cancer

China
Istituto Scientifico H. San Raffaele

Unknown

Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer

Lung Cancer

Italy
University of Sao Paulo

Completed

Effects of Betaine Supplementation on Strength and Muscle Creatine Content

Healthy Subjects

Brazil
Li-kun Chen

Recruiting

the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Brain Metastases

China
The First Affiliated Hospital of Zhengzhou University

Active, not recruiting

Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC)

Esophageal Squamous Cell Carcinoma

China
Kunming Medical University

Recruiting

A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

China
West China Hospital

Recruiting

PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer

Thyroid Cancer

China
The First Affiliated Hospital of Xinxiang Medical...

Recruiting

Observational Study of the Efficacy and Safety of Anlotinib Combined With Penpulimab in Elderly Lung Cancer Patients (AP)

Lung Cancer | Non Small Cell Lung Cancer | Lung Carcinoma | Non-small Cell Carcinoma | Lung Neoplasm

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer (TNBC)

China
Boehringer Ingelheim

Terminated

BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Japan
Hubei Cancer Hospital

Recruiting

Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC

NSCLC

China
Niguarda Hospital

Completed

Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells

Leukemia, Myeloid, Chronic-Phase

Italy
Novartis Pharmaceuticals

Terminated

Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

Switzerland, United States, Germany, Singapore, Korea, Republic of, Canada
Lahey Clinic

Completed

Lid Margin And Conjunctival Microbial Flora Following Punctum Occlusion

Dry Eye Syndrome

United States
Shanghai Chest Hospital
Changhai Hospital; Ruijin Hospital

Unknown

Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial

Lung Adenocarcinoma
Anqin Zhang

Not yet recruiting

ADCb (Anlotinib/Docetaxel/Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast Cancer

Breast Cancer

China
Zhejiang Cancer Hospital

Completed

Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations

Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Study of Anlotinib in Subjects With Advanced Malignancy

Advanced Malignancy

China
Tianjin Medical University Cancer Institute and...

Enrolling by invitation

Phase 2 Multi-center Randomized Study to the Efficacy and Safety of AK105 Combined With Anrotinib Hydrochloride in Patients With Recurrent/Refractory Classical Hodgkin's Lymphoma

Recurrent/Refractory Classical Hodgkin's Lymphoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

Hepatocellular Carcinoma

China
Shanghai Zhongshan Hospital

Unknown

Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma (ALTER-H-002)

Hepatocellular Carcinoma

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy

Esophageal Squamous Cell Carcinoma

China
Shanghai Chest Hospital

Recruiting

First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations

Non-Small Cell Lung Cancer (NSCLC)

China
Tang-Du Hospital

Completed

Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer

Sintilimab and Anlotinib in Combination With Chemotherapy

China
Cttq

Unknown

Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial

Gastrointestinal Stromal Tumors

China
Fudan University
Shanxi Province Cancer Hospital; Inner Mongolia Cancer Hospital Affiliated...

Recruiting

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Advanced Thyroid Cancer Patients Who Received Target Therapy

China
Zhejiang Cancer Hospital

Unknown

Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer

Biliary Tract Cancer

China
Ji Yongling

Not yet recruiting

Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC

Non-Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
Accelerated Community Oncology Research Network
Eli Lilly and Company; Genentech, Inc.

Completed

Phase II Study Alimta and Gemzar + Avastin as First Line Chemotherapy for Elderly Patients With Stage IIIB/IV NSCLC

Non-Small Cell Lung Cancer

United States
XSpray Microparticles

Completed

Pharmacokinetic Comparison of XS003 and Tasigna

Healthy

United Kingdom
Northwestern University
National Cancer Institute (NCI)

Unknown

Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases

Lymphoma | Brain and Central Nervous System Tumors | Metastatic Cancer

United States
University of Alabama at Birmingham
Ascenta Therapeutics

Withdrawn

Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer

Carcinoma, Non Small Cell Lung
First Affiliated Hospital of Wenzhou Medical University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Capsules in the Treatment for IPF/PF-ILDs

Interstitial Lung Diseases

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer

Advanced Head, Neck and Chest Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Cholangiocarcinoma

Advanced Cholangiocarcinoma

China
Nanfang Hospital of Southern Medical University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of Sequential Anlotinib Followed by EP Regimen Plus Concurrent Radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer

Unresectable Stage III Non-small Cell Lung Cancer

China
Rongjie Tao
National Natural Science Foundation of China

Unknown

High-dose Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases

Brain Metastases

China
Guangzhou University of Traditional Chinese Medicine
Guangdong Provincial Hospital of Traditional Chinese Medicine

Recruiting

Anlotinib Combined With mXELIRI as Second-line Treatment of Advanced Colorectal Cancer

Advanced Colorectal Cancer

China
Liu Zhenhua

Not yet recruiting

Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer

Extensive Stage Small Cell Lung Cancer

China
Huashan Hospital

Active, not recruiting

Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas

Malignant Glioma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer

Gynecological Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor

MSI-H or dMMR Advanced Solid Tumors

China

3

Subscribe